AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amgen (AMGN) PT Raised to $307 at UBS
May 3, 2024 7:06 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $307.00 (from $284.00) while maintaining a Neutral rating.
The analyst comments "The much anticipated MariTide interim completed (earlier than we expected) with mgmt providing positive qualitative commentary, as we had expected. At face... More
Amgen (AMGN) PT Lowered to $328 at RBC Capital
May 3, 2024 6:35 AM EDTRBC Capital analyst Gregory Renza lowered the price target on Amgen (NASDAQ: AMGN) to $328.00 (from $332.00) while maintaining a Outperform rating.
The analyst comments "GLP-1/GIPR, MariTides stated success on the ph.II interim data look internally takes the cake on the call,... More
